Better Therapeutics, Inc. (OTC:BTTX) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Capital Rahul Rakhit – LifeSci Capital Keay Nakae – Chardan Operator Good morning, and welcome to the Better Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Large accelerated filer ☐ Accelerated filer ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. Delaware 85-3472546 ( St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission File Number: 001-39864 BETTER THERAPEUTICS, INC. Delaware 85-3472546 ( State or other jurisdiction of incorporation or ...

as to don't major | a | major | major | major | man | more | man | m Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases MAY 2022 THERAPEUTICS Disclaimer This presentation ("Presentation") is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. ("BetterTx" or the "Company") nor any of its respective affiliates nor any of its or their control persons, officers, directors, employees or representatives ...

Better Therapeutics, Inc. (OTC:BTTX) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Â Company Participants Kevin Appelbaum – Co-Founder and Chief Executive Officer Mark Berman – Chief Medical Officer Mark Heinen – Chief Financial Officer Conference Call Participants Thomas Flaten – Lake Street Capital Charles Rhyee – Cowen Keay Nakae – Chardan Rahul Rakhit – LifeSci Capital Operator Good morning, and welcome to the Better Therapeutics First Quarter 2022 Financial Results and Business Update Confer ...

v UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39864 BETTER THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 85-3472546 (State or other jurisdic ...

as been and man a major | major | modern | man | more | man | manufacture | manufacture | www. COMPANY PRESENTATION | FEBRUARY 2022 Pioneering a prescription digital therapeutics platform for cardiometabolic diseases THERAPEUTICS Disclaimer This presentation ("Presentation") is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. ("BetterTX" or the "Company") nor any of its respective affiliates nor any of its or their c ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock BTTX The Nasdaq Stock Market LLC Emerging growth company ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39864 | --- | --- | |-----------------------------------------|---------------------------------------| | MOUNTAIN CR ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39864 | --- | --- | |-----------------------------------------|------------------------------------| | | | | MOUNTAI ...